Cerebrospinal fluid CD19(+) B-cell expansion in N-methyl-D-aspartate receptor encephalitis

Russell C Dale, Sekhar Pillai, Fabienne Brilot, Russell C Dale, Sekhar Pillai, Fabienne Brilot

Abstract

There is increasing interest in the role of autoantibodies in acquired autoimmune central nervous system disorders. N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune encephalitis defined by the presence of autoantibodies that bind to the NMDAR. Although there is evidence of NMDAR antibody pathogenicity, it is unclear which treatment results in the best outcome. We measured the proportion of B-cells in the cerebrospinal fluid of two children with NMDAR encephalitis (a 6-year-old male and a 4-year-old female), one in the acute phase and one in the relapsing phase. The proportion of CD19(+) B-cells in both children was greater than 10%, significantly higher than seen in non-inflammatory neurological disorders (<1%). This finding supports the use of drugs, such as rituximab, that deplete B-cells in severe or refractory cases of NMDAR encephalitis, and lends further support to the humoral autoimmune hypothesis in NMDAR encephalitis.

© The Authors. Developmental Medicine & Child Neurology © 2012 Mac Keith Press.

References

    1. Dalmau J, Lancaster E, Martinez-Hernandez E, et al.Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol2011; 10: 63-74.
    1. Vincent A, Bien CG, Irani SR, et al.Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol2011; 10: 759-72.
    1. Hughes EG, Peng X, Gleichman AJ, et al.Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci2010; 30: 5866-75.
    1. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, et al.Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology2011; 77: 589-93.
    1. Bien CG, Vincent A, Barnett MH, et al.Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain2012; 135: 1622-38.
    1. Dale RC, Tantsis E, Merheb V, et al.Cerebrospinal fluid B-cell expansion in longitudinally extensive transverse myelitis associated with neuromyelitis optica immunoglobulin G. Dev Med Child Neurol2011; 53: 856-60.
    1. Pranzatelli MR, Tate ED, Travelstead AL, et al.Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol2006; 28: 585-93.
    1. Pranzatelli MR, Travelstead AL, Tate ED, et al.B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology2004; 62: 1526-32.
    1. Dale RC, Brilot F, Fagan E, et al.Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation. Dev Med Child Neurol2009; 51: 317-23.
    1. Dale RC, Irani SR, Brilot F, et al.N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol2009; 66: 704-9.
    1. Bar-Or A, Fawaz L, Fan B, et al.Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?Ann Neurol2010; 67: 452-61.
    1. Bennett JL, Lam C, Kalluri SR, et al.Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol2009; 66: 617-29.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi